What's Happening

Stay up to date on conferences, social posts, and what’s new with Healthesystems

Events

Let’s connect at one of our upcoming conferences or speaking engagements

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Kombiglyze® XR (saxagliptin and metformin hydrochloride) extended-release tablets

Approval Date: Jul 2023

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

hello world!

RiVive (naloxone hydrochloride) nasal spray

Approval Date: Jul 2023

Note: New Product

Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA

hello world!

Spiriva® HandiHaler (tiotropium bromide) inhalation powder

Approval Date: Jun 2023

Note: First-Time Generic

For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

hello world!

Katerzia® (amlodipine benzoate) oral suspension

Approval Date: Jun 2023

Note: First-Time Generic

For the treatment of hypertension and coronary artery disease

hello world!

Fleqsuvy (baclofen) oral suspension

Approval Date: Jun 2023

Note: First-Time Generic

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

hello world!

Diastat® AcuDial (diazepam) rectal gel delivery system

Approval Date: May 2023

Note: First-Time Generic

Indicated for the management of selected, refractory, patients with epilepsy, on stable regimens of anti-epileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity

hello world!

Celontin® (methsuximide) capsules

Approval Date: May 2023

Note: First-Time Generic

Indicated for the control of absence (petit mal) seizures that are refractory to other drugs

hello world!

Yuflyma (adalimumab-aaty) injection

Approval Date: May 2023

Note: New Product

A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis

hello world!

Paxlovid (nirmatrelvir and ritonavir) tablets

Approval Date: May 2023

Note: New Product

Indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19

hello world!

Inpefa (sotagliflozin) tablets

Approval Date: May 2023

Note: New Product

Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes

hello world!

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmagnifiermenucross-circle